Self Testing Market Size, Share, Application Analysis and Growth by Forecast to 2022-2030


Self-testing kit sales are estimated to be worth US$ 7.49 billion globally. The market is anticipated to rise at a strong CAGR of 5.6% to reach US$ 11.55 Billion by 2030.

Self-Testing is opening new ways to monitor, diagnose, and address patients and their treatment. Manufacturers are developing testing kits for wellness and prevention strategies, ranging from chronic disorder management and acute infection diagnoses to detect the potential risks of ailments. Testing for drugs of abuse in the medical field is constructing new inroads into the domain of pain management, primarily owing to the increased usage of opioids for the treatment of chronic diseases as well as mortality and morbidity related to misuse of these drugs.

Get Full Access@

Key Findings of the Study

  • Global revenues will grow at 5.5% CAGR over forecast period, 2020-2030

  • Blood glucose testing to hold prominent share in self-testing market, owing to high prevalence rate of diabetes

  • Self-testing kits for testing urine and blood samples to account for greater demand through 2030

  • Retail and online pharmacies, will collectively capture nearly 60% revenue share

  • High-growth markets in APAC to witness heightened activity

“Lack of trust on accuracy and quality and reluctance of individuals to address health issues are key challenges before self-testing market players. Bringing regulations to effect, abidance with prevalent accreditations, and developing transparent solution to fulfil diagnostic requirements of individuals are the order of the day,” says analyst at FMI.

Self-testing Market – Competitive Intelligence
The global self-testing market is highly consolidated with top 5 years accounting for over three-fourths of total market revenue. Leading players are highly focusing on mergers & acquisitions (M&A) to remain competitive in global landscape. Case in point,

  • Procter & Gamble (P&G) has acquired This is L. Inc. – which is among fastest growing feminine care brands in the US – in order to further its commitments to support women and girls as well as its existing feminine care portfolio.

  • Ascensia Diabetes Care Holdings AG has teamed up with POCtech Co. co-develop and distribute continuous glucose monitoring systems.

  • bioMérieux – global leader in vitro diagnostics – has entered into an agreement with Baxter International Inc. – world leader in acute care – to design future biomarkers with the aim to rapidly recognize and offer treatment for acute kidney injury.

  • Siemens Healthineers has taken -based Fast Track Diagnostics (FTD) (Luxembourg), which is global supplier of molecular diagnostic tests.

Key Companies Profiled:

  • ACON Laboratories Inc.

  • ARKRAY Inc.

  • Assure Tech (Hangzhou) Co. Ltd.

  • Becton, Dickinson & Company

  • Bionime Corporation

  • Roche Holding AG

  • Quidel Corporation

  • True Diagnostics Inc.

Leave a Reply